Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model

BACKGROUND: The first antiarrhythmic drug to demonstrate a reduced rate of cardiovascular hospitalization in atrial fibrillation/flutter (AF/AFL) patients was dronedarone in a placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Matthew R, Nilsson, Jonas, Åkerborg, Örjan, Jhaveri, Mehul, Lindgren, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544268/
https://www.ncbi.nlm.nih.gov/pubmed/23326201
http://dx.doi.org/10.2147/CEOR.S36019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544268/
https://www.ncbi.nlm.nih.gov/pubmed/23326201
http://dx.doi.org/10.2147/CEOR.S36019

Ejemplares similares